Jubilant Biosys commences major capacity expansions for its Drug Discovery Services Business
- by Team ABLE - 02 Dec, 2019
Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Lifesciences Limited, has announced commencement of two expansion projects in Greater Noida and Bengaluru.
Owing to customer demand for its range of functional and integrated drug discovery services, Jubilant Biosyssays it has started design and construction of a brand new and state-of-the-art chemistry services laboratories on the existing Jubilant Greater Noida site.
The chemistry FTE capacity will be doubled and operations are expected to commence from H2 2020. The new site can accommodate up to 500 Chemistry FTE's. The site will be designed for the highest global compliance standards and deliver superior speed and quality in the entire drug discovery process.
In Bengaluru, Jubilant Biosys has obtained a 10-acre plot in the Devanahalli Industrial Park which is adjacent to the International Airport. A completely new drug discoveryservices site will be constructed in phases for further expansions.
In addition, the company has formed a new digital business unit comprising of Bio-Informatics, Data-curation for AI/ML, TrialStat EDC software as well as discovery focussed AI/ML capabilities. This business unit will also further expand on the new site and deliver increased benefits to its customers.
Marcel Velterop, President – Jubilant Biosys and CDMO, said, “The improving customer confidence earned through exemplary scientific execution and a positive outlook in the global drug discovery industry has resulted in the largest investment program in Jubilant Biosys since its inception. We will soon be able to offer our customers much improved capacity and services as well as ability to deliver an integrated IND package along with superior functional discovery services. A combination of the best talent and state-of-the-art technology and instrumentation will be offered to pursue drug discovery collaborations and help deliver new innovation to patients faster than ever.”
In addition, the company has formed a new digital business unit comprising of Bio-Informatics, Data-curation for AI/ML, TrialStat EDC software as well as discovery focussed AI/ML capabilities.